Drugs / pgDC + conserved HIV peptides
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03758625 | Jan 2019 → Feb 2025 | HIV infectious disease | Sharon Riddler | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pgDC + conserved HIV peptides | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03758625 ↗ |
| Modality | Vaccine | “Investigational vaccine composed of autologous dendritic cells matured with a standard prostaglandin E2 cocktail (pgDC) and loaded with a conserved HIV gag and pol peptide pool” NCT03758625 ↗ |